We are monitoring the impact of COVID-19 on Europe Multiple Myeloma Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Europe Multiple Myeloma Therapeutics Market Research Report - Segmented By Treatment Type, Drug Type & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends & Forecasts (2022 to 2027)

Published: January, 2022
ID: 801
Pages: 145

Europe Multiple Myeloma Therapeutics Market Size (2022 to 2027)

The Europe Multiple Myeloma Therapeutics Market was worth USD 2.07 billion in 2022 and is estimated to be growing at a CAGR of 4.58%, to reach USD 2.59 billion by 2027.

The growing number of improvements in the healthcare industry and the rising prevalence of hematological cancer are a few of the key factors driving the multiple myeloma therapeutics market in the European region. Specific genetic defects cause multiple myeloma. The disease is treated with medications that modify the immune system and help improve the efficacy of chemotherapies, radiation therapies, stem cell transplants, and platelet transfusions. Furthermore, increasing consumer awareness of the benefits of biologic treatment medications, which use the body's immune system to locate and target myeloma cells, boosts the market growth. Various technical advancements, such as the discovery of microRNA therapies and nanomedicines for treating multiple myeloma, are also working as growth stimulants. The substantial increase is expected due to the FDA's clearance of newer pharmaceuticals on the market.

However, the current therapy choices' complexity, inefficiency, and high costs necessitate improved methods that would significantly extend the lives of multiple myeloma patients. With monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors to the present therapies array, the medicines market is likely to gain traction. The rising frequency of the disease, the growing older population, and the inefficiency of current medication are driving the market forward in the forecast era. Furthermore, patients' demand for supporting treatment, such as point-of-care technologies, and the safety profile and efficacy of monoclonal antibodies, are expected to widen the drug treatment options available to them.

However, this market has its limitations. The tiny target patient group is a restricting factor that will play a role throughout the forecast period. The market may become saturated as new mAbs are introduced one after another, resulting in revenue stability. In addition, the market expansion will be limited by the high cost of therapy and legal restrictions. In addition, the market's growth is hampered by the high cost of radiotherapeutic equipment and the chemotherapy process. The major market restraint is healthcare providers' growing cost-consciousness. The launch and subsequent label extensions of these pipeline treatments will incur high costs, potentially affecting patient uptake of these drugs.

This research report on the Europe multiple myeloma therapeutics market has been segmented and sub-segmented into the following categories

By Treatment Type:

  • Chemotherapy      
    • Anthracycline antibiotic
    • Alkylating agent
  • Targeted Therapy
    • Proteasome inhibitor

By Drug Type:

  • Corticosteroids     
    • Dexamethasone (Decadron)
    • Prednisone (Deltasone/Orasone)
  • Immunomodulatory agents             
    • Thalidomide (Thalomid)
    • Lenalidomide (Revlimid)
    • Arsenic trioxide (Trisenox)
    • Plerixafor (Mozobil)

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Large-scale companies worldwide are investing more in product R&D, which has been suitable for the market in recent years. Advances in ongoing clinical studies relating to the treatment of the condition will provide a tremendous opportunity for market players. France is the EU's largest market for Multiple Myeloma drugs, whereas Italy and Spain are expected to increase at the fastest rates. Because of significant companies and advantageous reimbursement regulations, the European market is likely to grow dramatically, and the percentage of drugs approved by the FDA right away. Rather than competing for market share, these new treatments will be combined to create more effective treatment regimens, pushing sales for one another. When patients relapse, a new treatment plan will be implemented. This indicates that there are significant revenue-generating opportunities within the anticipated period.

KEY MARKET PLAYERS:

Companies playing a promising role in the Europe multiple myeloma therapeutics market profiled in this report are AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC. , ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc., and Johnson and Johnson.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation

                5.1 By Treatment Type

                                5.1.1 Chemotherapy      

                                                5.1.1.1 Anthracycline antibiotic

                                                5.1.1.2 Alkylating agent

                                5.1.2 Targeted Therapy

                                                5.1.2.1 Proteasome inhibitor

                5.2 By Drug Type                             

                                5.2.1 Corticosteroids      

                                                5.2.1.1 Dexamethasone (Decadron)

                                                5.2.1.2 Prednisone (Deltasone/Orasone)

                                5.2.2 Immunomodulatory agents             

                                                5.2.2.1 Thalidomide (Thalomid)

                                                5.2.2.2 Lenalidomide  (Revlimid)

                                                5.2.2.3 Arsenic trioxide  (Trisenox)

                                                5.2.2.4 Plerixafor  (Mozobil)

6. Geographical Analysis                                              

                6.1 Introduction                               

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Pipeline Product Analysis                                        

                7.1 Overview

                7.2 Pipeline Development Landscape                                    

                7.3 Molecular Targets in the Pipeline                                      

                7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)

                                7.4.1 Failure Rate            

                                7.4.2 Clinical Trial Duration           

                                7.4.3 Clinical Trial Size    

8. Strategic Analysis                                       

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental       

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services              

                                8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                        

                9.1 AB Science SA                            

                                9.1.1 Overview 

                                9.1.2 Product Analysis   

                                9.1.3 Strategic Evaluation and Operations            

                                9.1.4 Financial analysis  

                                9.1.5 Legal issues             

                                9.1.6 Recent Developments       

                                9.1.7 SWOT analysis       

                                9.1.8 Analyst View          

                9.2 AbbVie Inc.                 

                9.3 Ablynx NV                   

                9.4 Acceleron Pharma Inc.                           

                9.5 IGF Oncology LLC.                    

                9.6 ImmunGene Inc.                      

                9.7 Millennium Pharmaceuticals Inc.                       

                9.8 MimiVax LLC                              

                9.9 Mirna Therapeutics                 

                9.10 RedHill Biopharma Ltd.                        

                9.11 Rhizen Pharmaceuticals S.A.                             

                9.12 Terpenoid Therapeutics Inc.                             

10. Competitive Landscape                                         

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures    

                10.4 New Product Launches                       

11. Expert Opinions                                        

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Europe Multiple Myeloma Therapeutics Market By Region, From 2022 - 2027 (USD Billion)
  2. Europe Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  3. Europe Chemotherapy Market By Region, From 2022 - 2027 (USD Billion)
  4. Europe Targeted Therapy Market By Region, From 2022 - 2027 (USD Billion)
  5. Europe Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  6. Europe Corticosteroids Market By Region, From 2022 - 2027 (USD Billion)
  7. Europe Immunomodulatory agents Market By Region, From 2022 - 2027 (USD Billion)
  8. U.K Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  9. U.K Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  10. Spain Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  11. Spain Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  12. Germany Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  13. Germany Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  14. Italy Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  15. Italy Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  16. France Multiple Myeloma Therapeutics Market By Treatment Type, From 2022 - 2027 (USD Billion)
  17. France Multiple Myeloma Therapeutics Market By Drug Type, From 2022 - 2027 (USD Billion)
  18. Europe Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  19. Europe Anthracycline Antibiotic Market By Region, From 2022 - 2027 (USD Billion)
  20. Europe Alkylating Agent Market By Region, From 2022 - 2027 (USD Billion)
  21. U.K Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  22. Spain Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  23. Germany Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  24. Italy Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  25. France Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  26. Europe Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  27. Europe Melphalan (Alkeran) Market By Region, From 2022 - 2027 (USD Billion)
  28. Europe Liposomal doxorubicin (Doxil) Market By Region, From 2022 - 2027 (USD Billion)
  29. U.K Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  30. Spain Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  31. Germany Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  32. Italy Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  33. France Anthracycline Antibiotic Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  34. Europe Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  35. Europe Doxorubicin (Adriamycin) Market By Region, From 2022 - 2027 (USD Billion)
  36. Europe Cyclophosphamide (Neosar) Market By Region, From 2022 - 2027 (USD Billion)
  37. Europe Vincristine (Oncovin) Market By Region, From 2022 - 2027 (USD Billion)
  38. Europe Carmustine (BiCNU) Market By Region, From 2022 - 2027 (USD Billion)
  39. U.K Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  40. Spain Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  41. Germany Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  42. Italy Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  43. France Alkylating Agent Multiple Myeloma Chemotherapy Market By Type, From 2022 - 2027 (USD Billion)
  44. Europe Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  45. Europe Bortezomib (Velcade) Market By Region, From 2022 - 2027 (USD Billion)
  46. Europe Carfilzomib (Kyprolis) Market By Region, From 2022 - 2027 (USD Billion)
  47. U.K Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  48. Spain Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  49. Germany Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  50. Italy Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  51. France Multiple Myeloma Therapeutic Proteasome Inhibitors Market By Type, From 2022 - 2027 (USD Billion)
  52. Europe Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  53. Europe Dexamethasone (Decadron) Market By Region, From 2022 - 2027 (USD Billion)
  54. Europe Prednisone (Deltasone/Orasone) Market By Region, From 2022 - 2027 (USD Billion)
  55. U.K Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  56. Spain Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  57. Germany Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  58. Italy Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  59. France Multiple Myeloma Therapeutic Corticosteroids Market By Type, From 2022 - 2027 (USD Billion)
  60. Europe Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  61. Europe Thalidomide (Thalomid) Market By Region, From 2022 - 2027 (USD Billion)
  62. Europe Lenalidomide (Revlimid) Market By Region, From 2022 - 2027 (USD Billion)
  63. Europe Arsenic trioxide (Trisenox) Market By Region, From 2022 - 2027 (USD Billion)
  64. Europe Plerixafor (Mozobil) Market By Region, From 2022 - 2027 (USD Billion)
  65. U.K Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  66. Spain Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  67. Germany Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  68. Italy Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)
  69. France Multiple Myeloma Therapeutic Immunomodulatory Agents Market By Type, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample